Oxybutinin is used to relieve urge incontinence (inability to control urination) and frequent urination among other urinary and bladder difficulties by decreasing muscle spasms of the bladder. Brand names include Ditropan in tablet form and as a syrup, Lyrinel and Ditrospam in tablet form, Oxytrol, as a transdermal patch, and Gelnique, as a topical gel.
In April 2007, the US Food and Drug Administration (FDA) asserted that Ditropan, which is made by Johnson & Johnson, should include stronger warnings regarding the potential for hallucinations and related problems in children and elderly patients. The drugs label already warns of central nervous system risks, but the agencys representatives released documents in support of the need for more explicit warnings. A March 2007 memo also called on physicians to monitor for symptoms.
Oxybutinin shares adverse effects with those of other anticholinergic medications, including:
- dry mouth
- difficulty in micturition (urination)
- blurred vision
If you suspect that you or a loved one has been injured by taking, or having taken, Ditropan, you may be entitled to compensation. Contact a qualified pharmaceutical injury attorney for an evaluation of your case.
FDA safety information for Ditropan updated July 12, 2009 can be found at http://www.fda.gov/Safety/MedWatch/SafetyInformation/Safety-RelatedDrugLabelingChanges/ucm113884.htm.